Topical Ungual Formulations

• US 20080207537A1
• Filed: 06/06/2006
• Published: 08/28/2008
• Est. Priority Date: 06/06/2005
• Status: Abandoned Application

• Current Assignee: MedPharm Ltd
• Original Assignee: MedPharm Ltd
• Inventors: Brown, Marc Barry, Turner, Robert, Jones, Stuart Allen
• Application Number:
  US11/916,514
• Publication Number:
  US 20080207537A1
• Time in Patent Office: Days
• US Class Current: 514/31
• CPC Class Codes: A61K 33/40 Peroxides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/08 containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 31/10 Antimycotics

Abstract

Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.

Claims

1. A method for the treatment of an ungual condition treatable by a drug in a patient in need thereof, wherein a first preparation of a reducing agent and a second preparation of an oxidizing agent are separately disposed and sequentially administered to the nail of said patient in the order of first preparation followed by second preparation, said drug being disposed in said first preparation said second preparation, or, optionally, in a third preparation, said drug being additional to said reducing and said oxidising agents.

2. The method of claim 1, wherein a simple combination of said first and second preparations would lead to an extreme reaction, and wherein each agent is individually pharmaceutically acceptable to apply to a nail.

3. The method of claim 1, wherein said reducing agent is selected from the group consisting of:

ammonium thioglycolate, calcium thioglycolate, sodium thioglycolate, thioglycolic acid, and dithiothreitol, ascorbic acid, hydroquinone, mercaptoethanol, glutathione, L-cysteine, taurine, aminomethanesulfonic acid, cysteic acid, cysteinesulfinic acid, ethanedisulfonic acid, ethanesulfonic acid, homotaurine, hypotaurine, isethionic acid, mercaptoethanesulfonic acid, N-methyltaurine, and simple derivatives thereof.

4. The method of claim 3, wherein said derivative is a salt.

5. The method of claim 3, wherein said reducing agent is thioglycolic acid or a derivative thereof.

6. The method of claim 1, wherein said oxidizing agent is selected from the group consisting of:

urea, hydrogen peroxide, potassium persulfate, thiouracil, p-coumeric acid, glycolic acid, oxalic acid, cineol, peroxydone, chlorine dioxide, ammonium dichromate, ammonium nitrate, ammonium perchlorate, ammonium permanganate, barium bromate, barium chlorate, barium peroxide, cadmium chlorate, calcium chlorate, calcium chromate, calcium perchlorate, chromium nitrate, cobalt nitrate, silver oxide, periodic acid, and pyridine dichromate.

7. The method of claim 1, wherein said oxidizing agent is hydrogen peroxide.

8. The method of claim 1, wherein said oxidizing agent is an addition compound of hydrogen peroxide and urea.

9. The method of claim 1, wherein said drug is present in one or both of said preparations.

10. The method of claim 1, wherein said drug is present in a third preparation.

11. The method of claim 1, wherein the preparations are liquid.

12. The method of claim 1, wherein said reducing agent is prepared as an alkaline preparation, with a pH of between 7 and 14.

13. The method of claim 12, wherein the pH is between 8 and 13.

14. The method of claim 12, wherein the pH is between 9 and 12.

15. The method of claim 1, wherein the pH of said oxidizing agent is between 1 and 7.

16. The method of claim 15, wherein the pH is between 2 and 5.

17. The method of claim 1, wherein the preparations are aqueous.

18. The method of claim 1, comprising propylene glycol as a bulking agent.

19. The method of claim 1, wherein thioglycolic acid is conjugated with said drug.

20. The method of claim 1, wherein said drug is selected from the group of anti-fungal drugs consisting of:

amorolfine, miconazole, ketoconazole, itraconazole, fluconazole, econazole, ciclopirox, oxiconazole, clotrimazole, terbinafine, naftifine, amphotericin, griseofulvin, voriconazole, flucytosine, nystatin and pharmaceutically acceptable salts and esters thereof.

21. The method of claim 1, wherein said drug is terbinafine.

22. The method of claim 1, wherein said drug is amorolfine.

23. The method of claim 1, wherein drug is selected from the group of anti-psoriatic drugs consisting of:

corticosteroids, 5-fluorouracil, methotrexate, etretinate, cyclosporin, tacrolimus, and derivatives thereof.

24. The method of claim 1, wherein said oxidizing agent has a reduction potential, and wherein said reduction potential of 0.5 M of the said oxidizing agent in deionised water, when measured against an Ag/AgCl reference electrode, is less than −

50 mV.

25. The method of claim 24, wherein said reduction potential is less than −

100 mV.

26. The method of claim 24, wherein said reduction potential is less than −

200 mV.

27. The method of claim 1, wherein said reducing agent has a reduction potential, and wherein said reduction potential of 0.5 M of said reducing agent in deionised water, when measured against an Ag/AgCl reference electrode, is greater than +20 mV.

28. Use according to The method of claim 27, wherein the said reduction potential is greater than +50 mV.

29. The method of claim 27, wherein said reduction potential is greater than +75 mV.

30. The method of claim 1, wherein said reducing agent is conjugated with said drug.

31. The method of claim 1, wherein said oxidizing agent is conjugated with said drug.

32. The method of claim 1, wherein at least one of said preparations is selected from the group consisting of:

creams, ointments, gels, solutions, lotions, foams, mousses, sprays, pastes, dressings, powders, premixes, non-aqueous lacquers and aqueous lacquers.

33. The method of claim 1, wherein said preparations are each individually selected from the group consisting of:

creams, ointments, gels, solutions, lotions, foams, mousses, sprays, pastes, dressings, powders, premixes, non-aqueous lacquers and aqueous lacquers.

34. The method of claim 1, wherein at least one of said preparations is a water-based gel.

35. The method of claim 1, wherein all of said preparations are water-based gels.

36. The method of claim 1, wherein at least one of said preparations is a water-based lacquer.

37. The method of claim 1, wherein all of said preparations are water-based lacquers.

38. The method of claim 1, wherein said first preparation is applied at least 10 hours before the oxidising said second preparation.

39. The method of claim 1, wherein said first preparation is applied at least 15 hours before the said second preparation.

40. The method of claim 1, wherein said first preparation is applied at least 20 hours before the said second preparation.

41. The method of claim 1, wherein said third preparation is applied within an hour after application of said oxidizing agent preparation.

42. The method of claim 1, wherein said third preparation is applied within 20 minutes after application of said second preparation.

43. The method of claim 1, wherein said third preparation is applied immediately after application of said second preparation.

44. A method for the treatment of an ungual infection of a nail in a patient in need thereof, comprising applying a preparation of a reducing agent to said nail, followed by applying a preparation of an oxidizing agent thereto, said ungual condition being treatable by a drug, said drug being disposed in one of said preparations or in a third preparation.

45. canceled

46. A kit comprising a first preparation of a reducing agent and a second preparation of an oxidizing agent separately disposed therein, a drug to treat an ungual condition being disposed in said first preparation, said second preparation, or, optionally, in a third preparation, said drug being additional to said reducing and said oxidizing agents.